Predicted Neo-antigen Burden
Showing 1 - 25 of >10,000
Bladder Cancer, Melanoma Trial in United States (Nivolumab, Nivolumab plus Ipilimumab)
Active, not recruiting
- Bladder Cancer
- Melanoma
- Nivolumab
- Nivolumab plus Ipilimumab
-
Farmington, Connecticut
- +4 more
May 9, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +20 more
- Neoantigen Peptide Vaccine
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 7, 2022
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Orange, Chicago, Boston (rHSC-DIPGVax,
Recruiting
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- rHSC-DIPGVax
- +2 more
-
Orange, California
- +2 more
Nov 10, 2022
Relapsing Multiple Sclerosis Trial in Worldwide (Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- +5 more
-
Birmingham, Alabama
- +295 more
Jan 13, 2023
Malignant Melanoma, Metastatic, Non Small Cell Lung Cancer Metastatic, Bladder Urothelial Carcinoma, Metastatic Trial in Herlev
Active, not recruiting
- Malignant Melanoma, Metastatic
- +2 more
-
Herlev, Denmark
- +1 more
Jan 10, 2022
NSCLC, NSCLC Trial in Switzerland (Durvalumab, Radiotherapy)
Recruiting
- Non-small Cell Lung Cancer
- NSCLC
- Durvalumab
- Radiotherapy
-
Aarau, Switzerland
- +12 more
Oct 17, 2022
Early HER2-negative High-risk Breast Cancer and BRCA1/2
Not yet recruiting
- Breast Cancer
-
Arkhangelsk, Russian Federation
- +19 more
Jul 3, 2023
Triple Negative Breast Cancer Trial (Cryoablation, Cryoablation combined with PD1 Inhibitor)
Not yet recruiting
- Triple Negative Breast Cancer
- Cryoablation
- Cryoablation combined with PD1 Inhibitor
- (no location specified)
Mar 28, 2023
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of
Recruiting
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- 6-month course of antiandrogen drugs
- Long-term course of antiandrogen drugs
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023
Solid Tumor Trial in Wuhan (Neo-T, Cyclophosphamide, Fludarabine)
Recruiting
- Solid Tumor
- Neo-T
- +3 more
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Mar 23, 2023
Solid Tumor Trial in Shanghai (Neo-T, Cyclophosphamide, Fludarabine)
Recruiting
- Solid Tumor
- Neo-T
- +3 more
-
Shanghai, China
- +1 more
Mar 23, 2023
Sequent Extended Study
Not yet recruiting
- Coronary Artery Disease
- Ischemic Heart Disease
- Sequent Please Neo
- (no location specified)
Mar 26, 2023
Recurrent Glioblastoma Trial in Brussels (Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV,
Not yet recruiting
- Recurrent Glioblastoma
- Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
- +2 more
-
Brussels, BelgiumUZ Brussel
Oct 23, 2023
Severe Aortic Valve Stenosis Trial in Egypt, Lebanon, Saudi Arabia (Aortic valve replacement)
Not yet recruiting
- Severe Aortic Valve Stenosis
- Aortic valve replacement
-
Aswan, Egypt
- +6 more
May 4, 2023
Esophageal Cancer, Surgery, Neoadjuvant Treatment Trial in Zhengzhou (Neoadjuvant immunochemo)
Recruiting
- Esophageal Cancer
- +3 more
- Neoadjuvant immunochemotherapy
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzh
Oct 2, 2022
Soft Tissue Sarcoma Trial in France (Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior
Not yet recruiting
- Soft Tissue Sarcoma
- Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.
- Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).
-
Bordeaux, France
- +10 more
Aug 28, 2023
Esophageal Tumor Trial in China (cisplatin and paclitaxel)
Completed
- Esophageal Neoplasm
- cisplatin and paclitaxel
-
Beijing, Beijing, China
- +8 more
Oct 3, 2022
Coroflex® ISAR NEO PMCF Study y ( rEPIC07 )
Not yet recruiting
- Coronary Artery Disease (CAD)
- Ischemic Heart Disease
- Coroflex® ISAR NEO coronary stent system
- (no location specified)
Jan 16, 2023
Rheumatoid Arthritis Disease Activity and Sub Clinical
Completed
- Rheumatoid Arthritis
-
Assiut, EgyptAssiut university hospital
Jan 23, 2023
Metastatic Castrate-sensitive Prostate Cancer Trial in Germany, United States (Apalutamide, Androgen-deprivation Therapy (ADT))
Not yet recruiting
- Metastatic Castrate-sensitive Prostate Cancer
- Apalutamide
- Androgen-deprivation Therapy (ADT)
-
Lakewood, Colorado
- +5 more
May 23, 2023
INnovative and Micro-INvasive TEchniques for Early
Recruiting
- Breast Cancer
- Liquid biopsy and imaging
-
Aviano, Pordenone, ItalyCentro di Riferimento Oncologico
Apr 26, 2023
Node-positive Breast Cancer Trial (Targeted axillary lymph node dissection)
Not yet recruiting
- Node-positive Breast Cancer
- Targeted axillary lymph node dissection
- (no location specified)
Jan 6, 2023
Aortic Valve Disease, Cardiovascular Diseases Trial in Berlin (Venus-Neo Surgical Aortic Valve)
Not yet recruiting
- Aortic Valve Disease
- Cardiovascular Diseases
- Venus-Neo Surgical Aortic Valve
-
Berlin, GermanyDeutsches Herzzentrum Berlin-Charité
Jul 4, 2023
Insulin Resistance Trial in Madison (Oral Glucose Tolerance Test, 3 Tesla MRI, Intravenous Catheter)
Completed
- Insulin Resistance
- Oral Glucose Tolerance Test
- +3 more
-
Madison, WisconsinUniversity of Wisconsin-Madison
Aug 3, 2022
Unresectable Melanoma, Metastatic Melanoma Trial in Brussel, Amsterdam, Barcelona (NEO-PTC-01)
Recruiting
- Unresectable Melanoma
- Metastatic Melanoma
- NEO-PTC-01
-
Brussel, Belgium
- +2 more
Dec 5, 2022